Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence

doi:10.1016/j.cjca.2020.05.033

Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence

科研成果: 期刊稿件 › 社论 › 同行评审

源语言	英语
页（从-至）	1180-1182
页数	3
期刊	Canadian Journal of Cardiology
卷	36
期	8
DOI	https://doi.org/10.1016/j.cjca.2020.05.033
出版状态	已出版 - 8月 2020
已对外发布	是

!!!ASJC Scopus Subject Areas

心脏病学与心血管医学

访问文件

10.1016/j.cjca.2020.05.033

其它文件与链接

引用此

@article{e2a30fc973ad4082b472aef04fbb0a3e,

title = "Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence",

note = "Funding Information: S.Z. has received consulting fees from Novartis and participates in Novartis-sponsored clinical trials. B.C. has participated in consultation and speaking engagements for Novartis Pharmaceuticals, Servier Laboratories, and Boehringer Ingelheim Pharmaceuticals. S.C. was on the National Advisory Board of Novartis (March 2019). G.S. is on the Edwards Lifesciences Advisory Board. SV receives grants and honoraria from Novartis and Servier. The other authors have no conflicts of interest to disclose.",

year = "2020",

month = aug,

doi = "10.1016/j.cjca.2020.05.033",

language = "English",

volume = "36",

pages = "1180--1182",

journal = "Canadian Journal of Cardiology",

issn = "0828-282X",

publisher = "Pulsus Group Inc.",

number = "8",

}

TY - JOUR

T1 - Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic

T2 - Early Guidance and Evolving Evidence

N1 - Funding Information: S.Z. has received consulting fees from Novartis and participates in Novartis-sponsored clinical trials. B.C. has participated in consultation and speaking engagements for Novartis Pharmaceuticals, Servier Laboratories, and Boehringer Ingelheim Pharmaceuticals. S.C. was on the National Advisory Board of Novartis (March 2019). G.S. is on the Edwards Lifesciences Advisory Board. SV receives grants and honoraria from Novartis and Servier. The other authors have no conflicts of interest to disclose.

PY - 2020/8

Y1 - 2020/8

UR - http://www.scopus.com/inward/record.url?scp=85087983721&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087983721&partnerID=8YFLogxK

U2 - 10.1016/j.cjca.2020.05.033

DO - 10.1016/j.cjca.2020.05.033

M3 - Editorial

C2 - 32502522

AN - SCOPUS:85087983721

SN - 0828-282X

VL - 36

SP - 1180

EP - 1182

JO - Canadian Journal of Cardiology

JF - Canadian Journal of Cardiology

IS - 8

ER -